Hizentra from CSL - subcutaneous immunoglobulin pushes US home infusion care

By Julian Reed, ad hoc news New Launch Desk. Reviewed June 30, 2026, 6:52 PM ET. Details in the imprint.

Hizentra from CSL sits in a beige pump pack on a suburban Ohio kitchen table, the clear liquid warming in the user's hand before a once-a-week infusion. The therapy has quietly turned complex hospital immunoglobulin infusions into a home routine for thousands of US patients.

High-concentration Ig at home

Hizentra is a 20% liquid subcutaneous immunoglobulin (SCIG) preparation indicated in the US for adults and children with primary immunodeficiency and for adults with chronic inflammatory demyelinating polyneuropathy, or CIDP. The product is supplied ready to use in vials and prefilled syringes, eliminating the need for reconstitution. It can be infused using a mechanical infusion pump or, for some regimens, via manual push using syringes, which many patients prefer for shorter sessions.

Because Hizentra is designed for subcutaneous administration, patients typically infuse into fatty tissue in areas such as the abdomen or thighs, rotating injection sites to manage local reactions. In practice that means setting up a small pump or syringe on a kitchen table or living room sideboard, cleaning the skin, inserting fine needles, and watching TV while the dose goes in over 45 to 90 minutes. To qualify for therapy, patients are diagnosed by immunologists or neurologists and usually start with supervised infusions at a clinic before transitioning to self-administration at home.

US availability, pricing, and insurance

CSL markets Hizentra widely in the US through CSL Behring, and the drug is listed in major pharmacy and specialty distribution systems such as CVS Specialty and Accredo. The therapy is prescription-only, dispensed via specialty pharmacies that ship directly to patients along with infusion supplies. A single 20% 10 g/50 mL vial can be priced in the thousands of dollars at wholesale acquisition cost, although actual out-of-pocket costs vary significantly. Many commercial health plans, Medicare, and Medicaid cover Hizentra under medical or pharmacy benefits for FDA-approved indications, often subject to prior authorization requirements that verify diagnosis and need.

CSL runs a patient support program called Hizentra Connect and broader CSL Behring assurance programs to help patients navigate insurance, copay assistance, and nurse training. On CSL’s materials, nurses explain step-by-step setup of the infusion pump, skin preparation, and how to recognize and manage typical injection-site reactions such as mild swelling or redness that usually resolve within 24 hours. In interviews, CSL Behring’s US immunology medical director Dr. Mark Ballow has pointed to the flexibility of weekly or more frequent, smaller doses as a way to maintain steadier immunoglobulin levels compared with some monthly IV regimens.

Why patients and clinics shift to SCIG

Hizentra’s home-use design is central to its clinical and commercial role. For primary immunodeficiency, patients lack parts of the immune system and face recurrent infections; replacing immunoglobulin on a regular schedule helps reduce infection frequency and severity. Traditionally, many patients received intravenous immunoglobulin (IVIG) in hospitals or infusion centers, spending half a day hooked to a drip once a month. SCIG like Hizentra shifts therapy toward more frequent, shorter infusions at home, which can flatten peaks and troughs in IgG levels.

From a first-hand perspective, the change is tangible. One PID patient quoted in CSL materials describes hearing the soft whirr of the infusion pump beside their couch instead of the ambient noise of hospital monitors, while being able to pause mid-infusion to check on kids in another room. Neurology patients with CIDP report that home infusions reduce travel fatigue and allow them to time treatments around work schedules. Physicians note that subcutaneous dosing can lower the risk of some systemic adverse reactions seen with rapid IV infusions, though local injection-site reactions are more common.

Manufacturing and plasma supply

Hizentra is derived from human plasma, and that matters for both safety and investor analysis. CSL operates a large network of plasma collection centers, particularly in the US, and uses fractionation facilities to isolate immunoglobulin G (IgG) for products like Hizentra. Safety protocols include donor screening, viral inactivation steps, and removal processes designed to minimize the risk of transmitting pathogens such as HIV, hepatitis B, and hepatitis C. Each batch undergoes quality testing before release.

Scaling a product like Hizentra depends on stable plasma volumes and efficient fractionation operations. CSL’s CEO Paul McKenzie has repeatedly highlighted immunoglobulin therapies as a growth pillar, citing investment in collection center capacity and manufacturing upgrades. Investors watch metrics such as plasma volumes, donor incentives, and regulatory developments around plasma collection in the US and Europe because shifts can affect supply, product margins, and the pace of new indication studies for immunoglobulin brands.

Competition, indications, and data

Hizentra competes with other SCIG offerings, including Takeda’s Cuvitru and niche subcutaneous formulations from Grifols and Octapharma. In CIDP, the clinical data package for Hizentra stems from studies like the PATH trial, which showed that maintenance SCIG reduced relapse risk compared with placebo in patients who had previously responded to IVIG. The FDA approved Hizentra for CIDP in 2019 based on that evidence. In primary immunodeficiency, long-term extension studies have tracked infection rates and patient-reported outcomes across thousands of infusions, helping support weekly and biweekly dosing schedules.

Neurologists such as Dr. Jeffrey Allen at the University of Minnesota have discussed how CIDP therapy decisions balance IVIG, SCIG, steroids, and other immunosuppressants, with SCIG favored in some cases for its home-based flexibility once disease control is established. For immunology, subcutaneous Ig is often proposed for stable patients who prefer more autonomy. Clinical guidelines highlight patient choice, venous access challenges, and reactions history as reasons to consider switching routes, and products like Hizentra are frequently referenced as standard SCIG options.

US investor angle and CSL stock

For US investors, Hizentra is a key line item inside CSL’s broader immunoglobulin portfolio rather than a household brand, but its role in shifting care from high-cost hospital infusions to reimbursed home therapy is central to how analysts model CSL’s margins. Hizentra revenues are bundled with other immunoglobulin products, yet investor presentations consistently highlight subcutaneous therapy expansion, new indications, and geographic rollouts. CSL stock (ASX: CSL, ISIN US1729081059) is primarily listed in Australia with no direct US listing, so US investors typically access the company via foreign brokerage access or international platforms.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.